Mandate

Vinge advises ABG Sundal Collier, Carnegie and Nordea in connection with the listing of RevolutionRace on Nasdaq Stockholm

Vinge advises ABG Sundal Collier, Carnegie and Nordea in connection with the listing of RVRC Holding AB (publ) on Nasdaq Stockholm.

The offering price was SEK 75 per share, corresponding to a market value of for all outstanding shares in RevolutionRace of approximately SEK 8,469 million. Provided that the over-allotment option is exercised in full, the offering will comprise 37,784,094 shares or approximately SEK 2,834 million.

RevolutionRace offers high quality functional clothing for people with an active lifestyle. The company was founded in 2013 by Pernilla Nyrensten, CEO and Niclas Nyrensten, Creative Director. Since its inception, the founders have had the goal of creating multifunctional clothing with great fit, in the highest quality and at reasonable prices under the tag line "Nature is our playground". By selling clothes online, directly to consumers without unnecessary intermediaries, RevolutionRace can offer products that have an unbeatable value in terms of price, quality and design. Together with its customers, the company has grown rapidly and is selling its products to more than 35 countries.

Vinge’s team consisted of David Andersson, Rikard Lindahl and Anders Sundin Lundberg.

 

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026